Skip To Main Content
Baruch D. Kuppermann on Muck Rack

Baruch D. Kuppermann

As seen in: Nature, MDPI, Taylor & Francis Online, Healio, Healio Ophthalmology, Indian Journal of Ophthalmology, Ophthalmology Times Europe, Ophthalmology Times, Retinal Physician, touchOPHTHALMOLOGY
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Baruch D.

Contact Baruch D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

New Gildeuretinol Findings From Retina Society

|
By Baruch D. Kuppermann, Kenneth C Fan, Diana V. Do
| Retinal Physician Verified
Editor in Chief Diana V. Do, MD, interviews Kenneth C. Fan, MD, MBA, and Baruch D. Kuppermann, MD, PhD, about their Retina Society presentations on gildeuretinol. The following transcript has been edited for clarity. Diana V. Do, MD: Welcome to Retinal Physician. I’m Diana V. Do, MD. Today I’m joined by 2 leaders in retina, Kenneth C. Fan, MD, MBA, and Baruch D. “Barry” Kuppermann, MD, PhD. We’re talking about treatments in development for Stargardt disease.
Open in Who Shared Issue with article?

Response to the letter to the editor- phase III trials in retinal biosimilars: parity before pragmatism

|
By Ashish Sharma, Baruch D. Kuppermann
| Nature Verified
We thank the authors for their thoughtful comments regarding our editorial and appreciate their engagement with this timely and evolving topic [1]. We are encouraged that there is broad agreement on the central premise that the future of biosimilar regulation should move away from a uniform requirement for comparative phase III efficacy trials toward a more tailored, science-driven approach.
Open in Who Shared Issue with article?

Photic retinal injury: Time to move beyond case reports—A PRISM Study Group perspective

|
By Ashish Sharma, Carl D. Regillo, Baruch D. Kuppermann
| Nature Verified
Solar retinopathy and welding arc retinopathy represent the most frequently reported forms of photic retinal injury and are uncommon but clinically important causes of visual impairment resulting from excessive exposure to visible and ultraviolet light [12]. Despite being recognised for decades, our understanding of these conditions remains remarkably limited.
Open in Who Shared Issue with article?
See all 30 licensed articles (32 Total)